March 1973, when she developed a left pleural effusion. She was subsequently treated with a variety of chemotherapeutic agents which included cytoxan, methotrexate, 5-fluorouracil, prednisone, diethylstilboestrol, and a short trial of L-PAM. In May 1975 she was started on tamoxifen, 90 mg (60 mg/M2) twice daily, and halotestin, 10 mg (7 mg/M2) twice daily as a participant in a randomised trial to study the effect of increasing doses of tamoxifen with or without halotestin. Currently accepted tamoxifen doses vary from 10 to 20 mg twice daily.
Tamoxifen is a nonsteroidal antioestrogen used in the treatment of breast cancer. The drug has been relatively free of serious side effects, though ocular toxicity has been reported in 4 patients on high-dose therapy. ' The patient noted the onset of decreasing vision in about October 1976 after 17 months of treatment with tamoxifen and halotestin. The total dose of tamoxifen at that time was slightly greater than 90 g. A previous ocular examination in May 1976 showed a visual acuity of RE 6/9 (20/30) and LE 6/7 5 (20/25). The fundus examination was recorded as normal. Ophthalmological examination in October 1977 revealed a best corrected visual acuity of 6/15 (20/50) in each eye. Visual field testing with the IV4e and 14e white targets on the Goldmann perimeter showed peripheral constriction and central scotomas. The conjunctivae, corneae, and intraocular pressures were normal. Mild nuclear sclerosis and a few cortical spoke-like opacities were present on both lenses. Fundus examination (Fig. 1 ) revealed a myriad of tiny, refractile, intraretinal lesions at all levels of the sensory retina. These lesions were concentrated in both maculae but extended to the ora serrata. At the level of the retinal pigment epithelium there were 250 to 400 ,m diameter yellow-white granular areas which were most prominent posterior to the equator but were noted in the far peripheral retina as well. Cystoid macular oedema was present bilaterally. The optic discs were normal and the retinal arterioles appeared 177 mildly narrowed. A fluorescein angiogram showed that the deep granular areas were hypofluorescent, with no evidence of leakage, though many showed border and central hyperfluorescent areas (Fig. 2) . Cystoid macular oedema was prominent in the late phase of the angiogram (Fig. 3) .
Tamoxifen and halotestin were discontinued in March 1978 after a total of 158 g of tamoxifen. Tamoxifen is a nonsteroidal antioestrogen which binds to oestrogen-receptor proteins in the cytoplasm.' It is used in the treatment of metastatic breast cancer, particularly in postmenopausal patients with soft-tissue metastases. In the recommended dosage of 10-20 mg twice daily it has not been shown to cause ocular abnormalities. 9 It is structurally similar to a group of drugs with cationic amphiphillic properties. These compounds, which include triparanol (MER-29), chloroquine, chlorpromazine (Thorazine), thioridazine (Mellaril), and amiodarone, are characterised by a hydrophobic moiety and a positively charged hydrophilic side chain on the same molecule.'0-'2 Some of these compounds have been shown in vitro to form tight but reversible bonds with polar lipids, resulting in vivo in the accumulation of drug-polar lipid complexes in lysosomes.101' Whether this is the underlying mechanism in the ocular toxicity of these drugs and of tamoxifen awaits further study.
